Contact
 

Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health, discusses why HIV is still a problem during his interview on The Colbert Report.  Watch the interview...

 

On April 01, 2011, small and medium enterprises (SMEs) in Canada were invited to submit project proposals for the new Canadian HIV Technology Development (CHTD) program.  The CHTD falls under the Translating Basic Science into...

The National Institute of Allergy and Infectious Diseases (NIAID) invites applications to establish a Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery (CHAVI-ID). CHAVI-ID will support a coordinated, multidisciplinary team of...

The blog Science Speaks: HIV &TB News published a profile of Col. Nelson L. Michael, who is in charge of the U.S. Military HIV Research Program (MHRP) at the Walter Reed Army Institute of Research. Michael has visited Mozambique several times...

An HIV vaccine that could outwit the deadly virus could undergo human trials in as little as a year's time, scientists say. Read the full article...

The Sixth EDCTP Forum is now inviting interested organizations to sponsor the event. The Forum is one of the major conferences in Africa related to HIV/AIDS, malaria and tuberculosis. For more information, click...

The Translational Health Sciences and Technology Institute (THSTI), an autonomous institute of the Government’s Department of Biotechnology, and the International AIDS Vaccine Initiative (IAVI) has jointly announced an agreement to operate and...

Jerome H. Kim, M.D., of the U.S. Military HIV Research Program in Rockville, Md., discussed the search for antibodies that could help explain why some participants in the Thai-based RV144 HIV vaccine trial were protected against HIV. Read the...

See below for the full report.

IAVI announced the start of a multi-center Phase I trial in Africa to evaluate the safety and immunogenicity of a preventive AIDS vaccine candidate made up of two components. The trial, named B002, is the first to test these...

Global HIV Vaccine Enterprise, 64 Beaver Street, # 352, New York, NY 10004 | +1 212-461-3692 or toll free at +1-866-966-4483
All Content ©2005 - 2013 Global HIV Vaccine Enterprise   |   Terms of Use   |   Privacy Policy   |   Log In / My Account